FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

The FDA has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic hormone-sensitive prostate cancer in combination with an ARPI. This approval significantly expands the eligible patient population and offers a new potential standard of care, with studies showing a 33% reduction in progression or death risk.